Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors RE. Sanborn, MJ. Pishvaian, MK. Callahan, AM. Weise, BI. Sikic, OE. Rahma, DC. Cho, NA. Rizvi, RL. Bitting, A Starodub, A Jimeno, MJ Yellin, T Rawls, L Vitale, A Halim, H Zhang, T Keler
Title Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
Journal Journal of Clinical Oncology
Vol
Issue
Date
URL http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3001
Abstract Text Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3001-3001.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable Nivolumab + Varlilumab Phase Ib/II Actionable In a Phase I/II trial, Varlilumab and Opdivo (nivolumab) combination treatment resulted in partial response in 5% (2/41) and stable disease in 17% (7/41) of colorectal cancer patients, with infrequent treatment-induced increase of PD-L1 expression and CD8+ T cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3001-3001; NCT02335918). detail...
Unknown unknown ovarian cancer not applicable Nivolumab + Varlilumab Phase Ib/II Actionable In a Phase I/II trial, Varlilumab and Opdivo (nivolumab) combination treatment resulted in partial response in 10% (5/49) and stable disease in 39% (19/49) of ovarian cancer patients, with treatment-induced increase of PD-L1 expression and CD8+ T cells more common in patients with better responses (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3001-3001; NCT02335918). detail...